Julien Hadoux

Are G3 ENETS neuroendocrine neoplasms heterogeneous?

Fritz‐Line Vélayoudom‐Céphise, Pierre Duvillard, L. Foucan et al. · Endocrine Related Cancer · 2013 · 329 citations

Medicine, Oncology, Pathology +17

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study

Jonathan Strosberg, Nobumasa Mizuno, Toshihiko Doi et al. · Clinical Cancer Research · 2020 · 221 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

<i>SDHB</i> mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma

Julien Hadoux, Judith Favier, Jean‐Yves Scoazec et al. · International Journal of Cancer · 2014 · 204 citations · Full text

Medicine, Oncology, Pharmacology +14

Phase 3 Trial of Selpercatinib in Advanced <i>RET</i> -Mutant Medullary Thyroid Cancer

Julien Hadoux, Rossella Elisei, Marcia S. Brose et al. · New England Journal of Medicine · 2023 · 190 citations

Medicine, Oncology, Pharmacology +13

Impact of COVID-19 on healthcare organisation and cancer outcomes

A. Bardet, Aldéric Fraslin, J. Marghadi et al. · European Journal of Cancer · 2021 · 186 citations · Full text

Medicine, Health Care Management, Oncology +16